Welcome to our dedicated page for enGene Holdings news (Ticker: ENGN), a resource for investors and traders seeking the latest updates and insights on enGene Holdings stock.
enGene Holdings Inc. (NASDAQ: ENGN) is a clinical-stage biotechnology company pioneering the development of gene therapies aimed at enhancing patient lives. Utilizing a proprietary non-viral Dually Derivatized Oligochitosan (DDX) gene delivery platform, enGene focuses on localized delivery of therapeutics directly to mucosal tissues and other organs. This unique platform is designed to offer a safer alternative to viral vectors, enabling the delivery of DNA and various forms of RNA without triggering systemic immune responses.
The company's flagship program, EG-70 (detalimogene voraplasmid), is in pivotal Phase 2 clinical trials for treating non-muscle invasive bladder cancer (NMIBC) in patients unresponsive or naïve to Bacillus Calmette-Guérin (BCG). EG-70 is intended to stimulate both the innate and adaptive immune systems, creating a robust local immune response to target and eradicate tumors while minimizing systemic toxicity. Encouraging interim results are expected in mid-2024, with a goal to file a Biologics License Application (BLA) by early 2026.
enGene's recent business combination with Forbion European Acquisition Corp. brought approximately $138 million in gross proceeds, significantly bolstering its financial position. The company is leveraging these funds to advance EG-70 and other promising pipeline programs targeting gynecological/genitourinary (GYN/GU) malignancies and respiratory diseases. In addition, enGene has secured a $50 million loan agreement with Hercules Capital to further support its endeavors.
The appointment of Dr. Raj Pruthi as SVP of Urologic Oncology and Clinical Development underscores enGene's commitment to advancing its EG-70 program. Dr. Pruthi, with extensive experience in bladder cancer from his tenure at Johnson & Johnson Innovative Medicine, will play a pivotal role in engaging the urological community and driving clinical development.
As enGene continues to progress, it remains dedicated to mainstreaming genetic medicines and expanding its innovative DDX platform across various therapeutic areas. For more information, visit engene.com.
enGene Holdings Inc. (Nasdaq: ENGN) has reported the grant of inducement equity awards to seven newly-hired employees on September 30, 2024. The awards consist of non-qualified stock options to purchase a total of 183,000 common shares at an exercise price of $6.60 per share, equal to the closing price on the grant date. Each option has a 10-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years. The grants were made by the Company's independent Compensation Committee as an inducement for employment, in accordance with NASDAQ Listing Rule 5635(c)(4).
enGene Holdings Inc. (Nasdaq: ENGN) announced preliminary data from the pivotal cohort of the LEGEND study for detalimogene voraplasmid, their lead investigational product for high-risk, BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis). The data showed:
- 71% Complete Response (CR) rate at any time
- 67% CR rate at three months
- 47% CR rate at six months
- Favorable tolerability with no drug-related discontinuations
The results are consistent with Phase 1 findings, supporting detalimogene's potential as a foundational therapy for NMIBC. The company plans protocol refinements to potentially enhance clinical benefits. Detalimogene's profile, including ease of handling and administration, minimal storage requirements, and lack of post-procedural patient restrictions, positions it as a promising treatment option, especially for community practice settings where over 70% of urologists practice.
enGene Holdings Inc. (Nasdaq: ENGN) reported its Q3 2024 financial results and provided a business update. The company, focused on developing detalimogene voraplasmid for high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), remains on track to release preliminary LEGEND study data in September 2024. Key financial highlights include:
- Cash and cash equivalents of $257.7 million, providing runway into 2027
- Total operating expenses of $16.8 million for Q3 2024
- Net loss of $14.1 million, or $0.32 per share
The company also announced leadership changes, including Ron Cooper joining as CEO and the promotion of Dr. Raj Pruthi to Chief Medical Officer.
enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company, announced its participation in three upcoming investor conferences in September 2024. The company's lead program, detalimogene voraplasmid, is currently in a pivotal study for high-risk, BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis).
The conferences include:
- Morgan Stanley 22nd Annual Healthcare Conference on September 5
- Wells Fargo Healthcare Conference on September 6
- H.C. Wainwright 26th Annual Global Investment Conference on September 11
Presentations will be given by Ron Cooper (CEO), Raj Pruthi (CMO), and Alex Nichols (COO). Live webcasts will be available on the enGene website for 90 days after each event.
enGene Holdings Inc. (Nasdaq: ENGN) has granted an inducement equity award to its new CEO, Ron Cooper. The award consists of a non-qualified stock option to purchase 1,250,000 common shares at an exercise price of $8.81 per share, equal to the closing price on July 22, 2024. The option has a 10-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over three years. This grant, approved by the independent Compensation Committee, is in accordance with NASDAQ Listing Rule 5635(c)(4) and is designed to incentivize Mr. Cooper as he joins the company.
enGene Holdings Inc. (Nasdaq: ENGN) has appointed Ron Cooper as its new Chief Executive Officer and Board member, effective July 22, 2024. Cooper succeeds Jason Hanson, who will remain as a strategic advisor. The company also promoted Dr. Raj Pruthi to Chief Medical Officer.
Cooper brings extensive experience in drug development and commercialization, having previously served as President and CEO of Albireo Pharma. He also spent nearly 30 years at Bristol-Myers Squibb in various leadership roles.
enGene is advancing EG-70, its lead product candidate for BCG-unresponsive high-risk Non-Muscle Invasive Bladder Cancer (NMIBC). The company believes EG-70 has the potential to be the most practical treatment option for high-risk NMIBC, offering a unique combination of efficacy, tolerability, and ease of administration.
enGene (Nasdaq: ENGN) reported its Q2 2024 results, showing significant financial and strategic updates. The company has expanded its LEGEND study of EG-70 into high-risk papillary-only NMIBC and plans to release interim data by September 2024. enGene secured a $200 million private placement in February and has $264.8 million in cash as of April 2024, expected to fund operations into 2027. However, its net loss increased to $15.0 million from $6.5 million YoY due to rising operating expenses. Additionally, the company announced key leadership changes and the deprioritization of the EG-i08 program for cystic fibrosis.
enGene Holdings, a clinical-stage genetic medicines company, announced that their CEO, Jason Hanson, will present a corporate overview at the Jefferies Global Healthcare Conference.
The event will take place in New York City on June 5, 2024, at 12:30 p.m. ET.
enGene's lead program, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
The presentation will be webcast live and archived on the enGene website for 90 days.
enGene Holdings Inc. (Nasdaq: ENGN) announced an oral presentation at the American Urology Association 2024 Annual Meeting regarding its non-viral gene therapy EG-70 for BCG-unresponsive non-muscle invasive bladder cancer. The presentation highlights the rational design of EG-70 to address challenges faced by other treatment options. Promising Phase 1 data show complete response rates of 70% and 60% at three and six months, respectively, with encouraging safety results.
FAQ
What is the current stock price of enGene Holdings (ENGN)?
What is the market cap of enGene Holdings (ENGN)?
What is enGene Holdings Inc.'s primary focus?
What is the lead program of enGene?
How does EG-70 work?
What recent financial milestones has enGene achieved?
Who is leading enGene?
What are the anticipated milestones for EG-70?
How is enGene expanding its clinical programs?
What are the advantages of enGene's DDX platform?
What can investors expect from enGene in the near future?
Where can more information about enGene be found?
